Gan & Lee Pharmaceuticals Co., Ltd.SSE: 603087

Announcement on the Major Contract

Sep 24, 2025 · Issued by Gan & Lee Pharmaceuticals Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Sep 24, 2025

On 6ix: 6ix.com/news/announcement-on-the-major-contract-1

Announcement on the Major Contract

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Gan & Lee Pharmaceuticals Co., Ltd. on 6ix

Earlier from Gan & Lee Pharmaceuticals

Announcement on Canceling Repurchased Shares and Decreasing Registered Capital and Notification to CreditorsSep 8, 2025
Announcement on Results of Shareholding Reduction by Senior Management MembersAug 21, 2025
Announcement on the Result of Shareholding Reduction by Shareholder and DirectorAug 16, 2025
Announcement on Completion of Administration of the First Subject in Phase II Clinical Trial of GZR102 InjectionAug 9, 2025
Announcement on Resolutions of the 3rd Meeting of the 5th Board of SupervisorsAug 8, 2025

Later from Gan & Lee Pharmaceuticals

Announcement on the Implementation of Repurchase and Cancellation of Partial Restricted Shares in the 2022 and 2024 Restricted Stock Incentive PlansSep 27, 2025
Announcement on Convening the Q3 2025 Performance BriefingOct 25, 2025
Announcement on Canceling Board of Supervisors, Amending the "Articles of Association", Handling Industrial and Commercial Change Registration, and Revising Some Governance SystemsOct 31, 2025
Announcement on Resolutions of the 5th Meeting of the 5th Board of DirectorsNov 11, 2025
Announcement on Positive CHMP Opinion Received for Marketing Authorization Application (MAA) of Insulin Glargine Injection (Ondibta?)Nov 14, 2025

All Gan & Lee Pharmaceuticals news releases

Follow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.

Follow Gan & Lee Pharmaceuticals